Trevi Therapeutics (TRVI) PT Lowered to $8 at Needham & Company

Go back to Trevi Therapeutics (TRVI) PT Lowered to $8 at Needham & Company

Trevi Therapeutics (TRVI) Tops Q3 EPS by 6c

November 10, 2021 4:27 PM EST

Trevi Therapeutics (NASDAQ: TRVI) reported Q3 EPS of ($0.34), $0.06 better than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

... More